QNCX
$0.10
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases.
Intraday
Recent News
BC-Most Active Stocks
Elong Power Holding Ltd. 329,453,698 0.1034
Quince Therapeutics’ stock crashes on Phase III ataxia-telangiectasia failure
Quince Therapeutics’ lead asset eDSP failed to meet the primary or secondary endpoints in the pivotal NEAT trial.
Spotify upgraded, Pinterest downgraded: Wall Street's top analyst calls
Spotify upgraded, Pinterest downgraded: Wall Street's top analyst calls
Quince Therapeutics price target raised to $5 from $4 at D. Boral Capital
D. Boral Capital analyst Jason Kolbert raised the firm’s price target on Quince Therapeutics (QNCX) to $5 from $4 and keeps a Buy rating on the shares after the company said the last patient has completed their last visit in the pivotal Phase 3 NEAT clinical trial evaluating encapsulated dexamethasone sodium phosphate in patients with Ataxia-Telangiectasia. The firm cites the rolling of its valuation metrics out a year for the target bump. Claim 50% Off TipRanks Premium and Invest with Confidenc
June 2025's Promising Penny Stocks For Savvy Investors
As the U.S. markets navigate a landscape marked by geopolitical tensions and fluctuating oil prices, investors are keenly observing shifts in major indices like the Dow Jones and S&P 500. For those interested in exploring beyond established giants, penny stocks—often representing smaller or emerging companies—remain an intriguing investment area despite their somewhat outdated moniker. By focusing on financially robust penny stocks, investors can uncover potential opportunities that balance...